Upper GI 2017

Summary

• Incidence of adenocarcinoma is increasing • Overall prognosis is dismal (despite some advances), mainly due to: – locally advanced disease (we diagnose too late) – early lymph nodes metastasis (intense network of lymph vessels) – no well defined subtypes – treatment options are still insufficient (personalized: Herceptin only) • No EBV and MSI subtypes • PDL1-checkpoint-inhibition less effective? • HER2/neu still the only personalized treatment option • >7 regional lymph nodes • Standardized work flow in pathology embedding of whole tumor bed • Regression scores after neoadjuvant treatment

Institute of Pathology | Alexander Quaas

Gastrointestinal Cancer Group Cologne (GCGC)